Escalating Dose Study for Safety, Tolerability and Pharmacokinetics After Single and Multiple Dermal Administration of Two BAY1003803 Formulation Types With Two Concentrations Each in Healthy Male Volunteers, Applying a Double-blind, Vehicle-controlled Design and Including a Positive Control Group

Trial Profile

Escalating Dose Study for Safety, Tolerability and Pharmacokinetics After Single and Multiple Dermal Administration of Two BAY1003803 Formulation Types With Two Concentrations Each in Healthy Male Volunteers, Applying a Double-blind, Vehicle-controlled Design and Including a Positive Control Group

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs BAY 1003803 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 Sep 2017 to 5 Oct 2017.
    • 28 Sep 2017 Status changed from active, no longer recruiting to discontinued.
    • 10 Aug 2017 Planned End Date changed from 15 Oct 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top